Skip to main content

DiaGenic Gets $1.3M Grant for Alzheimer's Dx Project

NEW YORK (GenomeWeb News) – DiaGenic today said that it has received a NOK 7.8 million ($1.3 million) grant from the Norwegian Research Council for an Alzheimer's disease diagnostics program.

The Oslo, Norway-based firm said that the project is aimed at improving the robustness and reducing the cost of blood-based tests for Alzheimer's disease. Specifically, the project will focus on the use of microRNAs for early diagnosis of the disease.

Clinical samples will be sourced from DiaGenic's biobank and the HUNT Biosciences biobank, DiaGenic said.

"This new grant for development of blood based diagnostics for early Alzheimer's disease represents an important financial contribution," DiaGenic CEO Henrik Lund said in a statement.

Two months ago, DiaGenic inked a deal with GE Healthcare to develop a blood-based test using DiaGenic's gene expression profiling tools for the early detection of a disorder associated with Alzheimer's disease.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.